4 Applications of LCMS Testing in Drug Development and Clinical Research

Liquid chromatography-mass spectrometry (LC-MS) testing plays an integral role in the drug development life cycle. Before the advent of combinatorial chemistry, compounds were first extracted and separated and then analyzed using chemical test platforms such as mass spectrometry and nuclear magnetic resonance. However, after the introduction of combinatorial technologies, drug compounds are directly separated and analyzed using LC-MS assays. Hence, LC-MS testing has become crucial at every step of drug discovery and development. 

The primary reason for LC-MS becoming essential in all phases of drug development is that it combines the separation power of LC and detection capacities of MS units in a single instrument. LC separates analytes based on their differences in partitioning characteristics, while MS assesses compounds based on their mass-to-charge ratio. This feature provides superior speed, selectivity, and sensitivity. However, LC-MS method validation will remain crucial for ensuring robust and reliable study data. The current article highlights four applications of LC-MS testing in drug development and clinical research.

Screening of hit compounds

Mass spectrometry has inherent applications and characteristics similar to drug compounds. Different compounds will have unique mass spectra. Except for a few isomers, mass spectra can provide data on structural qualities. This feature makes mass spectrometers an ideal detector for liquid chromatography. The combined qualitative elements of liquid chromatography and mass spectrometry make it a reliable and efficient tool in screening hit compounds during early drug discovery studies. LC-MS can test the solubility, chemical and metabolic stability, protein binding rate, and membrane permeability of selected drug compounds.

Evaluating drug efficacy and selection of drug compounds

LC-MS are crucial in the success of several drug discovery studies. Properly designed early in vitro approaches can decipher the inherent properties of a drug product. These studies can predict clearance rates in animal models and relate them to evaluate system clearance efficiency. In vitro data guides researchers to predict in vivo clearance rate and thus calculate drug half-life and bioavailability.

Today researchers administer multiple compounds together to assess drug penetration in target tissues. Generally, 20 drugs are administered simultaneously. However, studies have also administered up to 100 compounds for rapidly assessing multiple drugs through LC-MS testing.

Identification and profiling of drug impurities

Identifying and profiling drug impurities are crucial to generate safe yet effective pharmaceutical products. These measures ensure that the active ingredient is safely developed and delivered. Moreover, regulatory authorities have stringent guidelines for monitoring impurities in pharmaceutical products. By far, LC-MS testing has emerged as an efficient and reliable technique for identifying and profiling drug impurities.

Must Read: How Bioanalytical Services Are Transforming Drug Development and Research

Quantitative assessment of trace-level small molecules

Due to their superior selectivity and sensitivity, MS units have now become the preferred choice of LC-MS detectors. However, recent advances in technologies and increased demand for novel therapies have resulted in regulatory requirements that single quadrupole systems may not be able to fulfill. Here LC-MS/MS systems come to the rescue. Multiple reaction monitoring is the most common approach used in MS/MS quantitation. This approach can determine quantities well beyond the required regulatory limits, proving crucial in detecting impurities at trace levels.